Based on the AtriCure Inc stock forecast from 8 analysts, the average analyst target price for AtriCure Inc is USD 39.64 over the next 12 months. AtriCure Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AtriCure Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, AtriCure Inc’s stock price was USD 30.72. AtriCure Inc’s stock price has changed by -3.00% over the past week, -14.74% over the past month and -14.55% over the last year.
No recent analyst target price found for AtriCure Inc
No recent average analyst rating found for AtriCure Inc
Company Overview AtriCure Inc
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Read Less
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internation...Read More
Frequently Asked Questions About AtriCure Inc (ATRC) Stock
Based on ratings from 8 analysts AtriCure Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATRC's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for ATRC is USD 39.64 over the next 12 months. The maximum analyst target price is USD 61 while the minimum anlayst target price is USD 26.
ATRC stock's Price/Earning ratio is 34.48.
Our analysis grades ATRC stock's Price / Earning ratio at F. This means that ATRC stock's Price/Earning ratio is above 52% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this ATRC may be a overvalued for its sector.
The last closing price of ATRC's stock was USD 30.72.
The most recent market capitalization for ATRC is USD 1.67B.
Based on targets from 8 analysts, the average taret price for ATRC is projected at USD 39.64 over the next 12 months.
This means that ATRC's stock price may go up by +29.02% over the next 12 months.
We can't find any ETFs which contains AtriCure Inc's stock.
As per our most recent records AtriCure Inc has 1,200 Employees.
AtriCure Inc's registered address is 7555 Innovation Way, Mason, OH, United States, 45040.
You can get more information about it from AtriCure Inc's website at https://www.atricure.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About AtriCure Inc (ATRC) Stock
Based on ratings from 8 analysts AtriCure Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATRC's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for ATRC is USD 39.64 over the next 12 months. The maximum analyst target price is USD 61 while the minimum anlayst target price is USD 26.
ATRC stock's Price/Earning ratio is 34.48.
Our analysis grades ATRC stock's Price / Earning ratio at F. This means that ATRC stock's Price/Earning ratio is above 52% of the stocks in the Medical Instruments & Supplies sector in the NSD exchange.
Based on this ATRC may be a overvalued for its sector.
The last closing price of ATRC's stock was USD 30.72.
The most recent market capitalization for ATRC is USD 1.67B.
Based on targets from 8 analysts, the average taret price for ATRC is projected at USD 39.64 over the next 12 months.
This means that ATRC's stock price may go up by +29.02% over the next 12 months.
We can't find any ETFs which contains AtriCure Inc's stock.
As per our most recent records AtriCure Inc has 1,200 Employees.
AtriCure Inc's registered address is 7555 Innovation Way, Mason, OH, United States, 45040.
You can get more information about it from AtriCure Inc's website at https://www.atricure.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATRC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
